These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9312796)

  • 1. [Antiretroviral treatment and resistance].
    Gómez-Cano M; Villalba N; Mas A; Holguín A; Soriano V
    Rev Clin Esp; 1997 Aug; 197(8):574-82. PubMed ID: 9312796
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D; Karmochkine M; Si Mohamed A; Piketty C; Kazatchkine MD; Belec L
    AIDS; 1998 May; 12(7):824-5. PubMed ID: 9619820
    [No Abstract]   [Full Text] [Related]  

  • 5. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HIV: to administer protease inhibitors early].
    Dtsch Med Wochenschr; 1996 Dec; 121(49):A49. PubMed ID: 8998916
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
    Conway B; Montessori V; Rouleau D; Montaner JS; O'Shaughnessy MV; Fransen S; Shillington A; Weislow O; Mayers DL
    Clin Infect Dis; 1999 Apr; 28(4):910-1. PubMed ID: 10825060
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors.
    Pérez-Olmeda M; Del Romero J; Rubio A; Ruiz L; Rodríguez C; Leal M; Clotet B; Soriano V
    J Med Virol; 2001 Feb; 63(2):85-7. PubMed ID: 11170042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and multidrug resistance.
    Emini EA; Graham DJ; Gotlib L; Condra JH; Byrnes VW; Schleif WA
    Nature; 1993 Aug; 364(6439):679. PubMed ID: 7689173
    [No Abstract]   [Full Text] [Related]  

  • 12. Zidovudine-resistant variants of HIV-1 in lung.
    Gates A; Coker R; Miller R; Mitchell D; Williamson J; Clarke J
    AIDS; 1997 Apr; 11(5):702-3. PubMed ID: 9108966
    [No Abstract]   [Full Text] [Related]  

  • 13. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 19. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
    Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
    Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
    Naeger LK; Miller MD
    Curr Opin Investig Drugs; 2001 Mar; 2(3):335-9. PubMed ID: 11575701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.